| Status: Superseded | |||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED JANUARY 2017. Refer to TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
|||
|
|||
Medicine details |
|||
| Medicine name | pomalidomide (Imnovid®) | ||
| Formulation | 1 mg, 2 mg, 3 mg and 4 mg capsules | ||
| Reference number | 2590 | ||
| Indication | In combination with dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy |
||
| Company | Celgene Ltd | ||
| BNF chapter | Malignant disease & immunosuppression | ||
| Assessment type | Resubmission | ||
| Status | Superseded | ||
| Advice number | 1315 | ||
| NMG meeting date | 15/04/2015 | ||
| AWMSG meeting date | 15/07/2015 | ||
| Ratification by Welsh Government | 27/08/2015 | ||
| Date of issue | 02/09/2015 | ||
| NICE guidance | TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib |
||